An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Futibatinib (Primary)
- Indications Cholangiocarcinoma
- Focus Expanded access; Therapeutic Use
- Sponsors Taiho Oncology
- 25 Apr 2023 Status changed from recruiting to completed.
- 13 Aug 2020 New trial record